The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes
Open accessAbstract
OBJECTIVES: Phytochemical-mediated modulation of cytochrome P450 (CYP) activity may underlie many herb-drug interactions. Single-time point phenotypic metabolic ratios were used to determine whether long-term supplementation of goldenseal ( Hydrastis canadensis ), black cohosh ( Cimicifuga racemosa ), kava kava ( Piper methysticum ), or valerian ( Valeriana officinalis ) extracts affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4/5 activity. METHODS: Twelve healthy volunteers (6 women) were randomly assigned to receive goldenseal, black cohosh, kava kava, or valerian for 28 days. For each subject, a 30-day washout period was interposed between each supplementation phase. Probe drug cocktails of midazolam and caffeine, followed 24 hours later by chlorzoxazone and debrisoquin (INN, debrisoquine), were administered before (baseline) and at the end of supplementation. Presupplementation and postsupplementation phenotypic trait measurements were determined for CYP3A4/5, CYP1A2, CYP2E1, and CYP2D6 by use of 1-hydroxymidazolam/midazolam serum ratios (1-hour sample), paraxanthine/caffeine serum ratios (6-hour sample), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour sample), and debrisoquin urinary recovery ratios (8-hour collection), respectively. The content of purported "active" phytochemicals was determined for each supplement. RESULTS: Comparisons of presupplementation and postsupplementation phenotypic ratio means revealed significant inhibition (approximately 40%) of CYP2D6 (difference, -0.228; 95% confidence interval [CI], -0.268 to -0.188) and CYP3A4/5 (difference, -1.501; 95% CI, -1.840 to -1.163) activity for goldenseal. Kava produced significant reductions (approximately 40%) in CYP2E1 only (difference, -0.192; 95% CI, -0.325 to -0.060). Black cohosh also exhibited statistically significant inhibition of CYP2D6 (difference, -0.046; 95% CI, -0.085 to -0.007), but the magnitude of the effect (approximately 7%) did not appear to be clinically relevant. No significant changes in phenotypic ratios were observed for valerian. CONCLUSIONS: Botanical supplements containing goldenseal strongly inhibited CYP2D6 and CYP3A4/5 activity in vivo, whereas kava inhibited CYP2E1 and black cohosh weakly inhibited CYP2D6. Accordingly, serious adverse interactions may result from the concomitant ingestion of goldenseal supplements and drugs that are CYP2D6 and CYP3A4/5 substrates. Kava kava and black cohosh may interact with CYP2E1 and CYP2D6 substrates, respectively. Valerian appears to be less likely to produce CYP-mediated herb-drug interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Goldenseal supplementation markedly inhibited the metabolism of midazolam, a CYP3A probe substrate, with an increase in exposure on the order of 40–60% [72,73].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herbal Medicines and Perioperative Care
Ang-Lee, M. K. (2001) · JAMA · doi:10.1001/jama.286.2.208 · Cited by 981
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B. J., Jones, S. A., Wisely, G. B., Serabjit‐Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 946
Indinavir concentrations and St John's wort
Piscitelli, S. C., Burstein, A. H., Chaitt, D. G., Alfaro, R. M., & Falloon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05712-8 · Cited by 873
Interactions Between Herbal Medicines and Prescribed Drugs
Izzo, A., & Ernst, E. (2012) · Drugs · doi:10.2165/00003495-200161150-00002 · Cited by 464
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
The effect of garlic supplements on the pharmacokinetics of saquinavir
Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D., & Falloon, J. (2002) · Clinical Infectious Diseases · doi:10.1086/324351 · Cited by 431
Effect of grapefruit juice on digoxin pharmacokinetics in humans
Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., & Funck‐Brentano, C. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)17221-8 · Cited by 387
Budzinski, J. W., Foster, B. C., Vandenhoek, S., & Arnason, J. T. (2000) · Phytomedicine · doi:10.1016/s0944-7113(00)80044-6 · Cited by 352
Cytochrome P450 phenotypic ratios for predicting herb‐drug interactions in humans
Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., & ANG, C. Y. W. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126913 · Cited by 345
Self-citationThe effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo
Gorski, J. C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.013 · Cited by 305
The interaction between St John's wort and an oral contraceptive
Hall, S. D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.08.009 · Cited by 286
Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity
Henderson, G. L., Harkey, M. R., Gershwin, M. E., Hackman, R. M., Stern, J. S., & Stresser, D. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00407-5 · Cited by 274
Regulation of CYP3A4 Expression in Human Hepatocytes by Pharmaceuticals and Natural Products
Raucy, J. L. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.533 · Cited by 249
Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin
Sugimoto, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.120025 · Cited by 229
The involvement of P-glycoprotein in berberine absorption
Pan, G., Wang, G., Liu, X., Fawcett, J. P., & Xie, Y. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.t01-1-910403.x · Cited by 225
Gurley, B. J., GARDNER, S., Hubbard, M. A., WILLIAMS, D., Gentry, W. B., CARRIER, J., KHAN, I., EDWARDS, D., & Shah, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.007 · Cited by 212
Self-citationEffects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity
Zou, L., Harkey, M. R., & Henderson, G. L. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01913-6 · Cited by 204
SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES
Sridar, C., Goosen, T. C., Kent, U. M., Williams, J. A., & Hollenberg, P. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.587 · Cited by 195
An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic.
Foster, B. C., Foster, M. S., Vandenhoek, S., Krantis, A., Budzinski, J. W., Arnason, J. T., Gallicano, K., & Choudri, S. (2001) · PubMed · Cited by 189
Kava kava: examining new reports of toxicity
Clouatre, D. L. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2003.07.005 · Cited by 184
Inhibition of Human Cytochrome P450 Activities by Kava Extract and Kavalactones
Mathews, J. M., Etheridge, A. S., & Black, S. R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1153 · Cited by 181
The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity
Wang, Z., Gorski, J. C., Hamman, M. A., Huang, S. M., Lesko, L. J., & Hall, S. D. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)00127-8 · Cited by 168
Venkataramanan, R., Ramachandran, V., Komoroski, B. J., Zhang, S., Schiff, P. L., & Strom, S. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15071-4 · Cited by 156
Russmann, S., Lauterburg, B. H., & Helbling, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-1-200107030-00036 · Cited by 156
Drug absorption in vitro model: filter-immobilized artificial membranes
Avdeef, A., Strafford, M., Block, E., Balogh, M. P., Chambliss, W. G., & Khan, I. A. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00191-9 · Cited by 153
Self-citationBrazier, N. C., & Levine, M. (2003) · American Journal of Therapeutics · doi:10.1097/00045391-200305000-00003 · Cited by 149
Foster, B. C., Vandenhoek, S., Hana, J., Krantis, A., Akhtar, M., Bryan, M., Budzinski, J. W., Ramputh, A., & Arnason, J. T. (2003) · Phytomedicine · doi:10.1078/094471103322004839 · Cited by 146
Chatterjee, P., & Franklin, M. R. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1391 · Cited by 146
The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity
Wang, Z. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.118522 · Cited by 144
Kava lactones and the kava-kava controversy
Whitton, P. A., Lau, A., Salisbury, A., Whitehouse, J. M., & Evans, C. S. (2003) · Phytochemistry · doi:10.1016/s0031-9422(03)00381-9 · Cited by 141
Markowitz, J. S. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00148-6 · Cited by 123
HERBAL SUPPLEMENTS: A POTENTIAL FOR DRUG INTERACTIONS IN TRANSPLANT RECIPIENTS
Barone, G. W., Gurley, B. J., Ketel, B. L., & Abul‐Ezz, S. R. (2001) · Transplantation · doi:10.1097/00007890-200101270-00012 · Cited by 111
Self-citationDrug Interaction Potential of Soy Extract and Panax Ginseng
Anderson, G. D., Rosito, G., Mohustsy, M. A., & Elmer, G. W. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253636 · Cited by 109
Kava extracts: Safety and risks including rare hepatotoxicity
Teschke, R., Gaus, W., & Loew, D. (2003) · Phytomedicine · doi:10.1078/0944-7113-00314 · Cited by 106
Triterpene Glycosides from Cimicifuga racemosa
Shao, Y., Harris, A., Wang, M., Zhang, H., Cordell, G. A., Bowman, M., & Lemmo, E. (2000) · Journal of Natural Products · doi:10.1021/np000047y · Cited by 104
Markowitz, J. S., Donovan, J. L., DeVane, C. L., Sipkes, L., & Chavin, K. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095340.32154.c6 · Cited by 103
Pharmacological effects of Cimicifuga racemosa
Borrelli, F., Izzo, A. A., & Ernst, E. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00378-3 · Cited by 103
Strandell, J., Neil, A., & Carlin, G. (2004) · Phytomedicine · doi:10.1078/0944-7113-00379 · Cited by 92
Composition and biological activity of traditional and commercial kava extracts
Côté, C. S., Kor, C., Cohen, J., & Auclair, K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.093 · Cited by 89
Donovan, J. L., DeVane, C. L., Chavin, K. D., Wang, J.-S., Gibson, B. B., Gefroh, H. A., & Markowitz, J. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001164 · Cited by 85
Markowitz, J. S. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.08.010 · Cited by 85
A systematic review of the safety of black cohosh
Huntley, A. L., & Ernst, E. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200310010-00010 · Cited by 85
Liver Function Test Abnormalities in Users of Aqueous Kava Extracts
CLOUGH, A. R., Bailie, R. S., & Currie, B. J. (2003) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-120025347 · Cited by 73
Li, W., Sun, Y., Liang, W., Fitzloff, J. F., & van Breemen, R. B. (2003) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1008 · Cited by 72
In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4.
Lefebvre, T., Foster, B. C., Drouin, C. E., Krantis, A., Livesey, J. F., & Jordan, S. A. (2004) · PubMed · Cited by 70
Palmer, J. L., Scott, R. J., Gibson, A., Dickins, M., & Pleasance, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01479.x · Cited by 68
Inhibition of Cytochrome P450 3A4 by Extracts and Kavalactones of Piper methysticum (Kava-Kava)
Unger, M., Holzgrabe, U., Jacobsen, W., Cummins, C. L., & Benet, L. Z. (2002) · Planta Medica · doi:10.1055/s-2002-36360 · Cited by 66
Holland, D. T., Godfredsen, K. A., Page, T., & Connor, J. D. (1998) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00590-2 · Cited by 63
Frye, R. F., & Stiff, D. D. (1996) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(96)00227-7 · Cited by 63
Zou, L., Henderson, G. L., Harkey, M. R., Sakai, Y., & Li, A. P. (2004) · Phytomedicine · doi:10.1078/0944711041495263 · Cited by 59
Influence of Goldenseal Root on the Pharmacokinetics of Indinavir
Sandhu, R. S., Prescilla, R. P., Simonelli, T. M., & Edwards, D. J. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003258660 · Cited by 59
Abourashed, E. A., & Khan, I. A. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1035 · Cited by 58
Self-citationAnalytical techniques for the determination of lactones inPiper methysticum forst
Ganzera, M., & Khan, I. A. (1999) · Chromatographia · doi:10.1007/bf02497298 · Cited by 39
Self-citationJohnson, B. M., & van Breemen, R. B. (2003) · Chemical Research in Toxicology · doi:10.1021/tx020108n · Cited by 36
Sautou, V., Chopineau, J., Terrisse, M. P., & Bastide, P. (1991) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(91)80459-p · Cited by 33
Valepotriates and valerenic acids in commercial preparations of valerian available in Australia.
Shohet, D., Wills, R. B. H., & Stuart, D. L. (2001) · PubMed · Cited by 30
Frye, R. F., & Branch, R. A. (1996) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(95)00380-0 · Cited by 20
Absorption, distribution and excretion of berberine.
Mb, B., Chavan, & Nk, D. (1969) · PubMed · Cited by 18
Analysis of sesquiterpenes in Valeriana officinalis by capillary electrophoresis.
Mikell, J. R., Ganzera, M., & Khan, I. (2001) · PubMed · Cited by 5
Self-citationDrug Interaction Potential of Soy Extract and Panax Ginseng
Anderson, G. D., Rosito, G., Mohustsy, M. A., & Elmer, G. W. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043006010
Research works printed but not linked: 6
- [4]Gurley BJ, Hagan DW. Herbal and dietary supplement interactions with drugs. In: McCabe BJ, Frankel EH, Wolfe JJ, editors. Handbook of Food-Drug Interactions. Boca Raton: CRC Press; 2003. pp. 259–293. [Google Scholar]
- [46]Ganzera M, Bedir E, Khan IA. Separation of Cimicifuga racemosa triterpene glycosides by evaporative light scattering detection. Chromatographia. 2000;52:301–304. [Google Scholar]
- [48]The Pharmacopeia of the United States Twenty-seventh Revision, and the National Formulary. 22. Rockville: United States Pharmacopeial Convention, Inc.; 2004. Disintegration and dissolution of dietary supplements; pp. 2645–2646. [Google Scholar]
- [49]Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2. Lawrence Erlbaum Associates Publishers; 1988. pp. 19–42. [Google Scholar]
- [50]Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003;31:1391–1397. doi: 10.1124/dmd.31.11.1391. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
- [61]Food and Drug Administration. Letter to health-care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury. Vol. 36. US Department of Health and Human Services; Rockville, MD: May/June, 2002. p. 4. Available at http://www.cfsan.fda.gov/~dms/addskava.html. [Google Scholar]
Cited by
Sorted by citations
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
Adverse Effects of Nutraceuticals and Dietary Supplements
Ronis, M. J. J., Pedersen, K. B., & Watt, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052844 · Cited by 393
An Overview of the Evidence and Mechanisms of Herb–Drug Interactions
Fasinu, P. S., Bouic, P. J., & Rosenkranz, B. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00069 · Cited by 221
Inhibition of Cytochrome P450 Enzymes
Correia, M. A., & Hollenberg, P. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_5 · Cited by 259
Metadata
- Authors
- GURLEY, B., GARDNER, S., HUBBARD, M., WILLIAMS, D., GENTRY, W., KHAN, I., & SHAH, A.
- Affiliations
- University of Mississippi (US)
- Corresponding author
- GURLEY, B
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-05
- Volume
- 77
- Issue
- 5
- Pages
- 415-426
- ISSN
- 0009-9236 (ISSN-L)
- PMC
- PMC1894911
- OpenAlex
- W1966006812
- Cited by
- 271
- References
- 58
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 8 · 2023: 5 · 2022: 12 · 2021: 12 · 2020: 16 · 2019: 10 · 2018: 12 · 2017: 4 · 2016: 7 · 2015: 15 · 2014: 15 · 2013: 15 · 2012: 20
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM071322, GM71322-01A2)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- goldenseal, Hydrastis canadensis, kava, black cohosh, Cimicifuga racemosa, Valeriana officinalis, cytochrome P450, herb-drug interactions, CYP2D6 inhibition, CYP2E1, CYP1A2, phytochemicals, herbal supplements, midazolam hydroxylation
- MeSH terms
- Adult, Aryl Hydrocarbon Hydroxylases, Caffeine, Capsules, Drug Administration Schedule, Female, Humans, Male, Midazolam, Phenotype, Time Factors, Valerian, Patient Selection, Dietary Supplements, Kava, Cimicifuga, Hydrastis, Herb-Drug Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review